Brief: Lipum Presents Good Tolerability Data On Novel Antibody SOL-116 At ACR 2024

Lipum AB (publ)

18/11/2024 09:46

Nov 18 (Reuters) - Lipum AB (publ)  LIPUM.ST :
    * PRESENTS PROMISING DATA ON NOVEL ANTIBODY SOL-116 AT ACR
2024
    * IN DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, SOL-116
DEMONSTRATED
EXCELLENT TOLERABILITY ACROSS ALL DOSE LEVELS
    * FINAL RESULTS FOR ENTIRE STUDY EXPECTED IN Q1 2025

Source text:  ID:nMFN6Xtyp5 
Further company coverage:  LIPUM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))